Company
Headquarters: Lianyungang, China
Employees: 28,903
CN¥346.69 Billion
CNY as of July 1, 2025
US$48.39 Billion
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Roche | $260.54 B |
| Novartis | $243.50 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $699.59 B |
| Johnson & Johnson | $374.29 B |
| AbbVie | $336.94 B |
| Novo Nordisk | $309.91 B |
| UnitedHealth Group | $279.90 B |
Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.
| Last Financial Reports Date | March 31, 2025 |
| Revenue TTM | CN¥29.19 B |
| EBITDA | CN¥7.66 B |
| Gross Profit TTM | CN¥25.19 B |
| Profit Margin | 23.44% |
| Operating Margin | 28.11% |
| Quarterly Revenue Growth | 20.10% |
Jiangsu Hengrui Medicine Co. Ltd has the following listings and related stock indices.
Stock: SSE: 600276 wb_incandescent